Patients with Alzheimer’s disease (AD) have decreased IGF-2 expression (compared with control subjects) in some brain regions, as was demonstrated in a number of studies using post-mortem brain samples [19,20,21]. The gene discussed is IGF2; the disease is Alzheimer disease.